{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:22:27Z","timestamp":1782894147768,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12872-016-0222-6","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T06:56:22Z","timestamp":1457420182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry"],"prefix":"10.1186","volume":"16","author":[{"name":"for the EARLY Registry Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm K.","family":"Gitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian A.","family":"Potthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Baumgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Buhck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ehmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Ouarrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Senges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"issue":"3","key":"222_CR1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00004872-200403000-00009","volume":"22","author":"AM Sharma","year":"2004","unstructured":"Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens. 2004;22(3):479\u201386.","journal-title":"J Hypertens"},{"issue":"9349","key":"222_CR2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903\u201313.","journal-title":"Lancet"},{"issue":"2","key":"222_CR3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjmed.2014.07.011","volume":"128","author":"S Bezalel","year":"2015","unstructured":"Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM. Angiotensin Converting Enzyme Inhibitor Induced Angioedema. Am J Med. 2015;128(2):120\u20135.","journal-title":"Am J Med"},{"key":"222_CR4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/VHRM.S22589","volume":"8","author":"AR De Caterina","year":"2012","unstructured":"De Caterina AR, Harper AR, Cuculi F. Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Health Risk Manag. 2012;8:299\u2013305.","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"222_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2004.04.005","volume":"47","author":"GB Appel","year":"2004","unstructured":"Appel GB, Appel AS. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis. 2004;47(2):105\u201315.","journal-title":"Prog Cardiovasc Dis"},{"key":"222_CR6","volume":"8","author":"EC Li","year":"2014","unstructured":"Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8, CD009096.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"222_CR7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/jhh.2014.43","volume":"28","author":"LP Hasvold","year":"2014","unstructured":"Hasvold LP, Bodegard J, Thuresson M, Stalhammar J, Hammar N, Sundstrom J, et al. Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients. J Hum Hypertens. 2014;28(11):663\u20139.","journal-title":"J Hum Hypertens"},{"issue":"7","key":"222_CR8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1751-7176.2012.00617.x","volume":"14","author":"J Roy","year":"2012","unstructured":"Roy J, Shah NR, Wood GC, Townsend R, Hennessy S. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. J Clin Hypertens (Greenwich). 2012;14(7):407\u201314.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"222_CR9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S22595","volume":"8","author":"TW Kurtz","year":"2012","unstructured":"Kurtz TW, Kajiya T. Differential pharmacology and benefit\/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133\u201343.","journal-title":"Vasc Health Risk Manag"},{"issue":"10","key":"222_CR10","first-page":"634","volume":"36","author":"JD Jones","year":"2011","unstructured":"Jones JD, Jackson SH, Agboton C, Martin TS. Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. Proc Natl Acad Sci U S A. 2011;36(10):634\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"222_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","volume":"13","author":"GL Bakris","year":"2011","unstructured":"Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"222_CR12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1472-8206.2007.00464.x","volume":"21","author":"F Zannad","year":"2007","unstructured":"Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol. 2007;21(2):181\u201390.","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"222_CR13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jhh.2013.6","volume":"27","author":"G Bonner","year":"2013","unstructured":"Bonner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27(8):479\u201386.","journal-title":"J Hum Hypertens"},{"issue":"6","key":"222_CR14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00129784-200606060-00012","volume":"6","author":"VR Anderson","year":"2006","unstructured":"Anderson VR, Perry CM, Robinson DM. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs. 2006;6(6):417\u201332.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"222_CR15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145\u201353.","journal-title":"N Engl J Med"},{"key":"222_CR16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2261-13-46","volume":"13","author":"AK Gitt","year":"2013","unstructured":"Gitt AK, Baumgart P, Bramlage P, Mahfoud F, Potthoff SA, Senges J, et al. EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry. BMC Cardiovasc Disord. 2013;13:46.","journal-title":"BMC Cardiovasc Disord"},{"key":"222_CR17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/jch.12603","volume":"17","author":"RE Schmieder","year":"2015","unstructured":"Schmieder RE, Potthoff SA, Bramlage P, Baumgart P, Mahfoud F, Buhck H, et al. Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. J Clin Hypertens (Greenwich). 2015;17:98\u2013104.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"28","key":"222_CR18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159\u2013219.","journal-title":"Eur Heart J"},{"key":"222_CR19","doi-asserted-by":"crossref","unstructured":"Bramlage P, Schmieder RE, Gitt AK, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Potthoff SA: The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin converting enzyme inhibitor ramipril in clinical trials versus routine practice\u2013insights from the prospective EARLY registry. Trials 2015:in press.","DOI":"10.1186\/s13063-015-1100-8"},{"issue":"9455","key":"222_CR20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217\u201323.","journal-title":"Lancet"},{"issue":"6","key":"222_CR21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/13543770903008536","volume":"19","author":"DW Laight","year":"2009","unstructured":"Laight DW. Therapeutic inhibition of the renin angiotensin aldosterone system. Expert Opin Ther Pat. 2009;19(6):753\u20139.","journal-title":"Expert Opin Ther Pat"},{"issue":"15","key":"222_CR22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"issue":"8","key":"222_CR23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3109\/10641969709083217","volume":"19","author":"AD Bremner","year":"1997","unstructured":"Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997;19(8):1263\u201385.","journal-title":"Clin Exp Hypertens"},{"issue":"16","key":"222_CR24","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1517\/14656566.2013.834887","volume":"14","author":"V Barrios","year":"2013","unstructured":"Barrios V, Escobar C. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? Expert Opin Pharmacother. 2013;14(16):2249\u201361.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"222_CR25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/HJH.0b013e328306ebe2","volume":"26","author":"G Reboldi","year":"2008","unstructured":"Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26(7):1282\u20139.","journal-title":"J Hypertens"},{"issue":"9","key":"222_CR26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.clinthera.2011.08.008","volume":"33","author":"R Petrella","year":"2011","unstructured":"Petrella R, Michailidis P. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management. Clin Ther. 2011;33(9):1190\u2013203.","journal-title":"Clin Ther"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0222-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:18:07Z","timestamp":1526638687000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2261\/16\/56"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1186\/s12872-016-0222-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726206825.793529337","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]},"article-number":"56"}}